Medicus Pharma Ltd.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
MDCX$1.83-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(expressed in United States dollars)
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss for the year | $(35,444,361) | $(11,155,516) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 1,512,194 | 713,119 |
| Non-cash interest expense | 429,061 | 74,005 |
| Change in operating lease right-of-use assets | 97,838 | 88,234 |
| Change in fair value of debentures | 583,823 | - |
| Loss of extinguishment of debentures | 25,000 | - |
| IPR&D - Teverelix | 8,717,475 | - |
| Foreign exchange gain/loss | 41,947 | - |
| Loss on SEPA settlements | 278,854 | - |
| Issuance cost related to SEPA | 300,000 | - |
| Cost of issuance of debentures | 111,725 | - |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses | 352,825 | (1,040,265) |
| Deferred financing costs | (99,305) | - |
| Accounts payable | 923,552 | 808,745 |
| Accrued expenses and other current liabilities | (438,802) | 358,018 |
| Operating lease liability | (142,612) | (70,080) |
| Related party payable | (25,983) | (23,491) |
| Net cash used in operating activities | (22,776,769) | (10,247,231) |
| Cash flows from financing activities | ||
| Proceeds from issuance of convertible promissory notes | - | 5,172,500 |
| Proceeds from initial public offering, net of offering expenses | - | 2,049,716 |
| Proceeds from issuance of common shares and warrants, net of issuance costs | 9,790,015 | 5,470,000 |
| Proceeds from issuance of debentures | 11,866,293 | - |
| Repayment of the debentures and other loan | (7,391,107) | - |
| Proceeds from issuance of common shares under SEPA | 8,427,416 | - |
| Proceeds from exercise of warrants | 9,874,998 | - |
| Proceeds from exercise of stock options | 162,400 | - |
| Costs to issue debentures | (136,726) | - |
| Issuance costs for common shares | (653,504) | - |
| Net cash provided by financing activities | 31,939,785 | 12,692,216 |
| Cash flows from investing activities | ||
| Net cash paid for Antev asset acquisition including transaction costs | (4,619,152) | - |
| Net cash used in investing activities | (4,619,152) | - |
| Foreign currency effect on cash and cash equivalents | (2,969) | - |
| Net increase in cash and cash equivalents during the year | 4,540,895 | 2,444,985 |
| Cash and cash equivalents, beginning of the year | 4,164,323 | 1,719,338 |
| Cash and cash equivalents, end of the year | 8,705,218 | 4,164,323 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.